VIM and Parkinson disease: To determine the role of KSM-66 in neuroprotection, we studied possible changes in peroxiredoxin I, VGF and vimentin expression by analyzing lysates of 6-OHDA treated SH-SY5Y cells as a model of Parkinson with pre/post treatment with 0.5 mg/ml KSM-66 for 24 h.